You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing
|
|---|---|
| Published in |
Blood, April 2015
|
| DOI | 10.1182/blood-2015-03-635169 |
| Pubmed ID | |
| Authors |
David M Kurtz, Michael R Green, Scott V Bratman, Florian Scherer, Chih Long Liu, Christian A Kunder, Kazuhiro Takahashi, Cynthia Glover, Colm Keane, Shingo Kihira, Brendan Visser, Jason Callahan, Katherine A Kong, Malek Faham, Karen S Corbelli, David Miklos, Ranjana H Advani, Ronald Levy, Rodney J Hicks, Mark Hertzberg, Robert S Ohgami, Maher K Gandhi, Maximilian Diehn, Ash A Alizadeh |
| Abstract |
Recent studies have shown limited utility of routine surveillance imaging for diffuse large B-cell lymphoma (DLBCL) patients achieving remission. Detection of molecular disease by immunoglobulin high-throughput sequencing (Ig-HTS) from peripheral blood provides an alternate strategy for surveillance. We prospectively evaluated the utility of Ig-HTS within 311 blood and 105 tumor samples from 75 patients with DLBCL, comparing Ig-HTS from the cellular (circulating leukocytes) and acellular (plasma cell-free DNA) compartments of peripheral blood to clinical outcomes and 18FDG PET/CT (n=173). Clonotypic immunoglobulin rearrangements were detected in 83% of patients with adequate tumor samples to enable subsequent monitoring in peripheral blood. Molecular disease measured from plasma, as compared to circulating leukocytes, was more abundant and more correlated with radiographic disease burden. Prior to treatment, molecular disease was detected in the plasma of 82% of patients compared to 71% in circulating cells (p=0.68). However, molecular disease was detected significantly more frequently in the plasma at time of relapse (100% vs. 30%; p = 0.001). Detection of molecular disease in the plasma often preceded PET/CT detection of relapse in patients initially achieving remission. During surveillance time-points prior to relapse, plasma Ig-HTS demonstrated improved specificity (100% vs. 56%, p<0.0001) and similar sensitivity (31% vs. 55%, p=0.4) compared to PET/CT. Given its high specificity, Ig-HTS from plasma has potential clinical utility for surveillance after complete remission. |
X Demographics
The data shown below were collected from the profiles of 21 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 10 | 48% |
| Spain | 2 | 10% |
| Unknown | 9 | 43% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 7 | 33% |
| Scientists | 7 | 33% |
| Practitioners (doctors, other healthcare professionals) | 5 | 24% |
| Science communicators (journalists, bloggers, editors) | 2 | 10% |
Mendeley readers
The data shown below were compiled from readership statistics for 221 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | <1% |
| Israel | 1 | <1% |
| United States | 1 | <1% |
| Ireland | 1 | <1% |
| Unknown | 217 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 34 | 15% |
| Student > Ph. D. Student | 28 | 13% |
| Student > Master | 27 | 12% |
| Other | 23 | 10% |
| Student > Bachelor | 16 | 7% |
| Other | 42 | 19% |
| Unknown | 51 | 23% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 76 | 34% |
| Biochemistry, Genetics and Molecular Biology | 32 | 14% |
| Agricultural and Biological Sciences | 27 | 12% |
| Immunology and Microbiology | 10 | 5% |
| Computer Science | 3 | 1% |
| Other | 14 | 6% |
| Unknown | 59 | 27% |
Attention Score in Context
This research output has an Altmetric Attention Score of 38. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 December 2023.
All research outputs
#1,100,870
of 25,837,817 outputs
Outputs from Blood
#815
of 33,771 outputs
Outputs of similar age
#13,414
of 281,100 outputs
Outputs of similar age from Blood
#19
of 335 outputs
Altmetric has tracked 25,837,817 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 33,771 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 7.7. This one has done particularly well, scoring higher than 97% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 281,100 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 95% of its contemporaries.
We're also able to compare this research output to 335 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 94% of its contemporaries.